nSTRIDE autologous protein solution is a groundbreaking new treatment for patients with arthritis. The treatment is somewhat similar to PRP treatment: a blood sample is obtained and centrifuged, resulting in a fluid sample containing a high concentration of growth factors, anti-inflammatory cytokines and white blood cells. The main difference between PRP and nSTRIDE APS is the high concentration of white blood cells in nSTRIDE. The early scientific results are promising. Particularly patients with arthritis who would otherwise require joint replacement surgery can benefit form an injection with nSTRIDE APS. More information can be found here and here.